← Stock Trading Canary · All insider profiles
INSIDER PROFILE · NO
Øystein Rekdal
Chief Executive Officer
Profile key: no|øystein rekdal
Purchase history
- Companies traded
- 1
- Purchases · 12M
- 1
- Purchases · 24M
- 1
- Average purchase
- NOK 99,984
- Gross purchase value
- NOK 99,984
- Last purchase
- 2025-12-11
- Completed 20D events
- 1.0
- Outcome status
- INSUFFICIENT_SAMPLE
Latest company: Lytix Biopharma ASA
Companies: Lytix Biopharma ASA
Post-purchase outcomes
Benchmark-relative outcomes are available against Oslo Bors Benchmark.
- Excess return = stock return − Oslo Bors Benchmark return over the same period.
- Hit rate = positive excess-return events ÷ completed events.
- Price coverage = valid point-in-time prices ÷ events mature enough for that period.
- Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 1Small sample | 100.0% (1/1) | 0.0% (0/1) | -7.5% | -7.5% | -7.5% |
| 20D | 1Small sample | 100.0% (1/1) | 0.0% (0/1) | -17.5% | -17.5% | -17.5% |
| 60D | 1Small sample | 100.0% (1/1) | 0.0% (0/1) | -14.2% | -14.2% | -14.2% |
| 120D | 1Small sample | 100.0% (1/1) | 0.0% (0/1) | -36.4% | -36.4% | -36.4% |
Research patterns
- First purchase in 12M
- 1/1
- Large purchase ≥ €100k
- 0/1
- Cluster buying · 15D
- 0/1
- Buying the dip · ≥20% below prior 52W high
- 0/1
- Routine / opportunistic
- Not classifiable
Counts are profile-wide, point-in-time research labels. They never affect the insider score or ranking.
Every completed outcome is shown; n<5 is descriptive small-sample evidence and is not scored. Disclosure-level observations published on the same date may share a return path and may not be statistically independent. These results never affect the insider score or ranking.